• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

西非布基纳法索恶性疟原虫中Pfcrt T76与Pfmdr-1 Y86突变之间的关系以及体外/体内氯喹抗性

Relationship between the Pfcrt T76 and the Pfmdr-1 Y86 mutations in Plasmodium falciparum and in vitro/in vivo chloroquine resistance in Burkina Faso, West Africa.

作者信息

Tinto Halidou, Ouédraogo Jean Bosco, Erhart Annette, Van Overmeir Chantal, Dujardin Jean-Claude, Van Marck Eric, Guiguemdé Tinga Robert, D'Alessandro Umberto

机构信息

Institut de Recherche en Sciences de la Santé, Bobo Dioulasso, Burkina Faso.

出版信息

Infect Genet Evol. 2003 Nov;3(4):287-92. doi: 10.1016/j.meegid.2003.08.002.

DOI:10.1016/j.meegid.2003.08.002
PMID:14636690
Abstract

The relationship between Pfcrt T76 and Pfmdr-1 Y86 mutations in Plasmodium falciparum was explored in samples from patients with uncomplicated malaria and tested in vitro and in vivo with chloroquine (CQ) in Burkina Faso. The two mutations were strongly related. The Pfcrt T76 mutation was found in 82% of the samples having the Pfmdr-1 Y86 mutation too (odds ratio (OR)=4.8 [95% CI: 1.7-13.3]; P=0.002). However, only half (16/34) of samples with Pfcrt T76 mutation had also the Pfmdr-1 Y86 mutation. The latter was apparently associated with in vitro resistance (OR=4.8 [95% CI: 1.4-16.5]; P=0.01) but such association disappeared (P=0.77) after adjusting for the presence of the Pfcrt T76 mutation. This suggests that the occurrence of the Pfmdr-1 Y86 mutation is dependent on that of Pfcrt T76 mutation and could explain previous reports linking the Pfmdr-1 Y86 mutation with CQ resistance (CQR). The isolates carrying both the Pfcrt K76 and Pfmdr-1 N86 alleles (wild/wild (WW)) and the single mutant Pfmdr-1 Y86 (WM) had the lowest IC50 geometric mean (GMIC50) values, while those carrying both Pfcrt T76/Pfmdr-1 Y86 alleles (mutant/mutant (MM)), and the single mutant Pfcrt T76 (MW) had the highest. Among pre-treatment samples there was a strong linkage disequilibrium with an excess of MM and WW and a deficit of single mutants (MW and WM), suggesting that parasite fitness is higher for the former and lower for the latter.

摘要

在布基纳法索,对非重症疟疾患者的样本进行研究,探讨恶性疟原虫中Pfcrt T76与Pfmdr-1 Y86突变之间的关系,并在体外和体内用氯喹(CQ)进行测试。这两种突变密切相关。在也具有Pfmdr-1 Y86突变的样本中,82%发现有Pfcrt T76突变(优势比(OR)=4.8 [95%置信区间:1.7 - 13.3];P = 0.002)。然而,具有Pfcrt T76突变的样本中只有一半(16/34)也具有Pfmdr-1 Y86突变。后者显然与体外耐药性相关(OR = 4.8 [95%置信区间:1.4 - 16.5];P = 0.01),但在对Pfcrt T76突变的存在进行校正后,这种关联消失了(P = 0.77)。这表明Pfmdr-1 Y86突变的发生依赖于Pfcrt T76突变,并且可以解释先前将Pfmdr-1 Y86突变与氯喹耐药性(CQR)联系起来的报道。携带Pfcrt K76和Pfmdr-1 N86等位基因(野生/野生(WW))以及单突变Pfmdr-1 Y86(WM)的分离株具有最低的IC50几何平均值(GMIC50),而携带Pfcrt T76/Pfmdr-1 Y86等位基因(突变/突变(MM))以及单突变Pfcrt T76(MW)的分离株具有最高值。在治疗前样本中,存在强烈的连锁不平衡,MM和WW过多,单突变体(MW和WM)不足,这表明前者的寄生虫适应性较高,后者较低。

相似文献

1
Relationship between the Pfcrt T76 and the Pfmdr-1 Y86 mutations in Plasmodium falciparum and in vitro/in vivo chloroquine resistance in Burkina Faso, West Africa.西非布基纳法索恶性疟原虫中Pfcrt T76与Pfmdr-1 Y86突变之间的关系以及体外/体内氯喹抗性
Infect Genet Evol. 2003 Nov;3(4):287-92. doi: 10.1016/j.meegid.2003.08.002.
2
Chloroquine-resistance molecular markers (Pfcrt T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina Faso.布基纳法索的氯喹抗性分子标记(Pfcrt T76和Pfmdr-1 Y86)及阿莫地喹抗性
Trop Med Int Health. 2008 Feb;13(2):238-40. doi: 10.1111/j.1365-3156.2007.01995.x.
3
Point mutations in the pfcrt and pfmdr-1 genes of Plasmodium falciparum and clinical response to chloroquine, among malaria patients from Nigeria.尼日利亚疟疾患者中恶性疟原虫pfcrt和pfmdr - 1基因的点突变及对氯喹的临床反应
Ann Trop Med Parasitol. 2003 Jul;97(5):439-51. doi: 10.1179/000349803235002489.
4
Chloroquine-treatment failure in northern Ghana: roles of pfcrt T76 and pfmdr1 Y86.加纳北部氯喹治疗失败:疟原虫氯喹抗性转运蛋白(pfcrt)第76位密码子和疟原虫多重耐药蛋白1(pfmdr1)第86位密码子的作用
Ann Trop Med Parasitol. 2005 Dec;99(8):723-32. doi: 10.1179/136485905X75395.
5
Plasmodium falciparum pfcrt and pfmdr1 polymorphisms are associated with the pfdhfr N108 pyrimethamine-resistance mutation in isolates from Ghana.恶性疟原虫的pfcrt和pfmdr1基因多态性与来自加纳的分离株中pfdhfr基因第108位密码子的乙胺嘧啶抗性突变相关。
Trop Med Int Health. 2001 Oct;6(10):749-55. doi: 10.1046/j.1365-3156.2001.00792.x.
6
Evolution of the pfcrt T76 and pfmdr1 Y86 markers and chloroquine susceptibility 8 years after cessation of chloroquine use in Pikine, Senegal.塞内加尔皮金停止使用氯喹 8 年后,pfcrt T76 和 pfmdr1 Y86 标记物的演变和氯喹敏感性。
Parasitol Res. 2012 Oct;111(4):1541-6. doi: 10.1007/s00436-012-2994-7. Epub 2012 Jun 17.
7
High frequency of Plasmodium falciparum chloroquine resistance marker (pfcrt T76 mutation) in Yemen: an urgent need to re-examine malaria drug policy.在也门恶性疟原虫氯喹耐药标记(pfcrt T76 突变)高频出现:急需重新审查疟疾药物政策。
Parasit Vectors. 2011 May 27;4:94. doi: 10.1186/1756-3305-4-94.
8
Rapid detection of Pfcrt and Pfmdr1 mutations in Plasmodium falciparum isolates by FRET and in vivo response to chloroquine among children from Osogbo, Nigeria.通过荧光共振能量转移(FRET)快速检测尼日利亚奥索博儿童恶性疟原虫分离株中的Pfcrt和Pfmdr1突变以及对氯喹的体内反应。
Malar J. 2007 Apr 11;6:41. doi: 10.1186/1475-2875-6-41.
9
Dynamic of plasmodium falciparum chloroquine resistance transporter gene Pfcrt K76T mutation five years after withdrawal of chloroquine in Burkina Faso.布基纳法索停用氯喹五年后恶性疟原虫氯喹抗性转运蛋白基因Pfcrt K76T突变情况
Pan Afr Med J. 2015 Jun 9;21:101. doi: 10.11604/pamj.2015.21.101.6437. eCollection 2015.
10
Prevalence of crt and mdr-1 mutations in Plasmodium falciparum isolates from Grande Comore island after withdrawal of chloroquine.氯喹停用后大科摩罗岛恶性疟原虫分离株中crt和mdr-1突变的流行情况
Malar J. 2016 Aug 15;15(1):414. doi: 10.1186/s12936-016-1474-4.

引用本文的文献

1
Identification of the drug/metabolite transporter 1 as a marker of quinine resistance in a NF54×Cam3.II genetic cross.在NF54×Cam3.II基因杂交中鉴定药物/代谢物转运体1作为奎宁抗性的标志物。
bioRxiv. 2024 Oct 1:2024.09.27.615529. doi: 10.1101/2024.09.27.615529.
2
[Polymorphisms in parasites and mutations in the resistance genes and in Nanoro area, Burkina Faso].[布基纳法索纳诺罗地区寄生虫的多态性以及抗性基因的突变]
Pan Afr Med J. 2021 Jun 10;39:118. doi: 10.11604/pamj.2021.39.118.26959. eCollection 2021.
3
Prevalence of antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014.
2011年至2014年加蓬东南部抗疟药物耐药基因的流行情况。
Infect Drug Resist. 2018 Aug 28;11:1329-1338. doi: 10.2147/IDR.S160164. eCollection 2018.
4
Prevalence of Plasmodium falciparum Molecular Markers of Antimalarial Drug Resistance in a Residual Malaria Focus Area in Sabah, Malaysia.马来西亚沙巴州一个残留疟疾流行重点地区恶性疟原虫抗疟药物耐药性分子标志物的流行情况
PLoS One. 2016 Oct 27;11(10):e0165515. doi: 10.1371/journal.pone.0165515. eCollection 2016.
5
Prevalence of anti-malarial resistance genes in Dakar, Senegal from 2013 to 2014.2013年至2014年塞内加尔达喀尔抗疟疾耐药基因的流行情况。
Malar J. 2016 Jul 7;15(1):347. doi: 10.1186/s12936-016-1379-2.
6
In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso.在布基纳法索,蒿甲醚-本芴醇和双氢青蒿素-哌喹对恶性疟原虫Pfcrt和Pfmdr1变体的体内选择
Antimicrob Agents Chemother. 2015 Jan;59(1):734-7. doi: 10.1128/AAC.03647-14. Epub 2014 Nov 17.
7
Role of Pfmdr1 in in vitro Plasmodium falciparum susceptibility to chloroquine, quinine, monodesethylamodiaquine, mefloquine, lumefantrine, and dihydroartemisinin.Pfmdr1在恶性疟原虫对氯喹、奎宁、单去乙基氨喹啉、甲氟喹、本芴醇和双氢青蒿素的体外易感性中的作用。
Antimicrob Agents Chemother. 2014 Dec;58(12):7032-40. doi: 10.1128/AAC.03494-14. Epub 2014 Sep 8.
8
In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene.体外吡喹酮敏感性与恶性疟原虫氯喹耐药转运蛋白基因无关。
Malar J. 2013 Nov 25;12:431. doi: 10.1186/1475-2875-12-431.
9
Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study.2010 年塞内加尔达喀尔地区恶性疟原虫对抗疟药物的敏感性:一项离体和耐药分子标志物研究。
Malar J. 2013 Mar 20;12:107. doi: 10.1186/1475-2875-12-107.
10
Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal.塞内加尔达喀尔地区恶性疟原虫耐药相关分子标志物的流行情况。
Malar J. 2012 Jun 13;11:197. doi: 10.1186/1475-2875-11-197.